A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery among patients with CRSwNP.

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markersFull analysis of Phase 2 ...

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

Among patients in endoscopic remission at one year of treatment in VIVID ... response were observed with mirikizumab at Week 52 in the overall population (58.2% versus 48.8%; p=0.0075). Data from two ...

SAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...

Efficacy and safety of endoscopic retrograde cholangiopancreatography (ERCP) vs percutaneous transhepatic biliary drainage (PTBD) for cholangiocarcinoma biliary obstruction: An updated systematic ...